Hemostemix (CVE:HEM) Stock Price Up 29.4% – Still a Buy?

by · The Markets Daily

Hemostemix Inc. (CVE:HEM – Get Free Report) was up 29.4% during trading on Saturday . The company traded as high as C$0.11 and last traded at C$0.11. Approximately 602,760 shares changed hands during trading, an increase of 511% from the average daily volume of 98,700 shares. The stock had previously closed at C$0.09.

Hemostemix Price Performance

The company has a current ratio of 0.04, a quick ratio of 0.48 and a debt-to-equity ratio of -55.07. The firm’s 50-day moving average price is C$0.09 and its two-hundred day moving average price is C$0.10. The stock has a market cap of C$20.73 million, a PE ratio of -4.07 and a beta of 1.25.

About Hemostemix

(Get Free Report)

Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery.

See Also